Get the Stockscreener App
3.52
1.95%
-0.07
After Hours:
3.55
0.03
+0.85%
Aclaris Therapeutics Inc stock is traded at $3.52, with a volume of 1.50M.
It is down -1.95% in the last 24 hours and up +12.46% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
See More
Previous Close:
$3.59
Open:
$3.53
24h Volume:
1.50M
Relative Volume:
0.68
Market Cap:
$426.23M
Revenue:
$7.83M
Net Income/Loss:
$-64.92M
P/E Ratio:
-6.6453
EPS:
-0.5297
Net Cash Flow:
$-47.22M
1W Performance:
-5.88%
1M Performance:
+12.46%
6M Performance:
+76.88%
1Y Performance:
+117.28%
1-Day Range:
$3.44
$3.60
1-Week Range:
$3.20
$3.78
52-Week Range:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.52 | 434.70M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Vanguard (ACRS) Amends Schedule 13G; Reports 0 Shares After Realignment - Stock Titan
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis - MyChesCo
Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst - MarketBeat
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Published on: 2026-03-22 04:18:49 - baoquankhu1.vn
Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data - Investing.com
Deep Track Capital, LP Acquires Significant Stake in Aclaris Therapeutics Inc - GuruFocus
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The Manila Times
Aclaris Therapeutics Announces ePoster Presentation on Phase 2a Trial Results of ATI-2138 for Moderate-to-Severe Atopic Dermatitis at AAD Annual Meeting 2026 - Quiver Quantitative
New eczema trial results from Aclaris will debut at dermatology meeting - Stock Titan
Aclaris stock maintained at Buy by H.C. Wainwright on trial progress - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
Aclaris completes enrollment in atopic dermatitis trial By Investing.com - Investing.com Canada
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings - MarketBeat
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bitget
Aclaris Therapeutics completes enrollment in phase 2 trial of bosakitug (ATI-045) in atopic dermatitis - marketscreener.com
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis - TradingView
Aclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026 - Quiver Quantitative
109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan
Deep Track entities hold 9.35M Aclaris shares (ACRS) — 7.01% stake - Stock Titan
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Aclaris Therapeutics Raises $20 Million in Equity Financing - The Globe and Mail
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aclaris Therapeutics (NASDAQ: ACRS) sells 5.7M shares to raise $20M - Stock Titan
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):